Drug treatment in dementia

Current Opinion in Psychiatry

Volumn 14, Issue 4, 2001, Pages 349-353

  Bullock, R ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID; CHOLINESTERASE INHIBITOR; ESTROGEN; GALANTAMINE; STATIN; VACCINE;

ANTIINFLAMMATORY ACTIVITY; DEMENTIA; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; IMMUNIZATION; PUBLICATION; REVIEW; TREATMENT PLANNING;

EID: 0034914308     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200107000-00019     Document Type: Review

References (56)

1. A controlled trial of selegilene, alpha tocopherol, or both as treatment for Alzheimer's disease
2. B-peptide immunisation; a possible new treatment for Alzheimer's disease
3. Weighing the benefits of new Alzheimer's treatments
4. Donepezil therapy in clinical practice; a randomised crossover study
5. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
6. Effectiveness of rivastigmine in Alzheimer's disease
7. A 5-month, randomized, placebo-controlled trial of galantamine in AD
8. Galantamine in AD; a six month randomized, placebo-controlled trial with a 6-month extension
9. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: A multi-centre, randomised, controlled trial
10. Extended release physostigmine in Alzheimer Disease; a multicenter, double-blind, 12-week study with dose enrichment
11. Treatment of Alzheimer's disease
12. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
13. Gene dose of the epsilon 4 allele of apolipoprotein and disease progression in late onset Alzheimer's disease
14. Metrifonate treatment of AD; influence of APOE genotype
15. Lu-259, a muscarinic agonist, fails to improve cognition in Alzheimer's disease
16. Reactive oxygen species and antioxidant vitamins: Mechanisms of action
17. Are reactive oxygen species involved in Alzheimer's disease?
18. Vitamin E protects nerve cells from amyloid B protein toxicity
19. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation
20. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischaemic attacks
21. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men
22. Effect of oestrogen during menopause on risk of Alzheimer's disease
23. Estrogen for Alzheimer's disease in women
24. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease
25. Effects of estrogen on cognition, mood and cerebral blood flow in Alzheimer's disease: A controlled study
26. Estrogen and Alzheimer disease: Plausible theory, negative clinical trial
27. Estrogen actions in the central nervous system
28. Estrogen reduces neuronal generation of Alzheimer b-amyloid peptides
29. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease; results of a placebo-controlled, double-blind pilot study
30. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease; a review of 17 epidemiologic studies
31. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists; The Cache County Study
32. Anti-inflammatory drugs protect against Alzheimer disease at low doses
33. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease
34. A randomized controlled trial of prednisone in Alzheimer's disease
35. Anti-inflammatory drugs and Alzheimer-type pathology in aging
36. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse
37. Statins and the risk of dementia
38. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-methylglutaryl-coenzyme A reductase inhibitors
39. Cholinesterase inhibitors: A new class of psychotropic compounds
40. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale
41. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
42. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer disease in nursing care facilities
43. Olanzapine use in the elderly: A retrospective analysis
44. Gender differences in the treatment of behavior problems in Alzheimer's disease
45. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients
46. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone
47. A randomised trial of risperidone, placebo and haloperidol for behavioural symptoms of dementia
48. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomised, double-blind trial
49. Sorting out sleep in patients with Alzheimer's disease
50. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients
51. Sleep disturbances and tryptophan in patients with Alzheimer's disease
52. Hypersexuality in patients with dementia: Possible response to cimetidine
53. Coma in a patient with Alzheimer's disease taking low dose trazodone and gingko biloba
54. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer's disease: Power calculations and estimates of sample size to detect treatment effects
55. Methods for discerning disease-modifying effects in Alzheimer's disease treatment trials